Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Current Deferred Revenue (2016 - 2025)

Cytokinetics (CYTK) has disclosed Current Deferred Revenue for 9 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue changed N/A to $1.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.6 million, a N/A change, with the full-year FY2025 number at $1.6 million, changed N/A from a year prior.
  • Current Deferred Revenue was $1.6 million for Q4 2025 at Cytokinetics, roughly flat from $1.6 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $52.4 million in Q1 2025 to a low of $1.3 million in Q2 2025.